Releasing Pain, Reclaiming Self-Love: Karly Bannister Heals Others Through Education, Empowerment, and Chinese Medicine
You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media.
Karly Bannister's past has been defined by pain for too long. Having felt the impact of early traumatic experiences, she became too familiar with feeling scared and alone—or not feeling anything at all. Today, a confident CEO, homeowner, and mother, she no longer carries her burdens in silence. And, as a devoted acupuncturist blending the ancient wisdom of Chinese medicine with modern Western science, she helps others reclaim that sense of freedom.
Bannister's professional career spans 15 years of clinical experience and 30 years as a patient—a time that helped her refine her approach that is intuitive, joyful, personalized, and science-based. But the seeds of her love of holistic medicine were planted much earlier. "It all started with my grandfather," she shares. Watching a loved one struggle with Lou Gehrig's disease (ALS) changed something in her, especially as no conventional treatments were available at that time. "My father took it upon himself to learn different healing modalities, and I would assist, learning along the way," Bannister adds.
In parallel to her grandfather's health decline, Bannister was struggling herself. As a child with asthma and allergies, she remembers feeling like an outsider, unable to run, exercise, or simply play like her peers. At just eight years old, she was also diagnosed with obesity, placed on cholesterol medication, and put on a strict diet. She then needed braces and headgear while the pressures of puberty also weighed heavily on her. It was the beginning of a long and painful journey—one centered on never feeling comfortable in her own body.
Keahi Health Clinic
When her father took Bannister to her first acupuncture treatment at 14 years of age, it changed her life. She was able to become the athlete she had always wanted to be, finding solace and safety in movement. Exercise became a way of life, and the school gym became her sanctuary. But it wasn't only about physical health; it was about finding a space where she could belong while connecting with and experiencing confidence in her body. For most of her life, Bannister has utilized several methods of therapy, including somatic techniques, to recover from bulimia and manage complex trauma and ADHD. Throughout her life, movement remained a daily practice where she always felt most at peace.
However, while in the depths of her abusive marriage, Bannister was severely discouraged from exercising and other forms of self-care. She experienced fear, isolation, and overwhelm. "It reached a point where I didn't recognize myself anymore," she says. "I thought I was failing, that I was broken. In reality, I was trapped in a cycle of emotional abuse. This realization was the beginning of my healing. I then turned to my friends, family, and patients for support. My acupuncture clinic was a haven during a dark time in my life. It's truly an honor to now share proven self-healing methods to help my patients who supported me. "
Starting with small steps, Bannister reclaimed her confidence by treating her daily habits as sacred self-care rituals. Whether it was walking outside with her daughter and her dog, participating in exercise classes, or connecting with friends and family, she was able to let go of grief and find herself again. This time, empowered with the healing properties of Chinese medicine coupled with somatic therapy, she promised herself never to let go of the joy and happiness she rediscovered.
Her story, beyond personal transformation, laid the foundation for Bannister's career, which started at a renowned oriental medicine school. Working as the assistant to a premier acupuncturist in the area, serendipity did its work. Driven by her mentor's advice, Bannister packed her bags and accepted a one-of-a-kind opportunity to complete her postgraduate studies in hospitals, working alongside medical doctors at a major university in China. From China, Bannister began her career as an acupuncturist onboard a cruise ship.
She immediately had a full schedule of new patients each and every week. For nine months, she honed her skills while traveling the world—from the vast Caribbean waters to the picturesque glaciers of Alaska. During her undergraduate education, she studied abroad in Seville, Spain, for six months. After graduation, she taught English in Costa Rica for three months. Today, these culturally vibrant and clinically diverse experiences enrich her practice, fusing time-honored Eastern medical knowledge with the exciting advances in Western science.
When Bannister founded her practice in 2011, she did more than establish a purpose-driven business. She created a refuge where she became a partner for life, truly providing holistic health care. Her specialization is vast, including pediatrics, stress relief, weight loss, pain management, women's health, and hormonal balancing. The latter two are especially important for this passionate healer, as they fuel her mission of empowering women.
A voice of love and wisdom, Bannister's mission is also about education and empowerment. By providing practical advice and effective tools to more people, she hopes to multiply her positive impact and cause ripples of hope and healing. She achieves this in part through her signature Flow Method, a technique to elevate anxious energy to a place of calm, confidence, and clarity. Additionally, inspired by her clients' requests, Bannister has expanded into public speaking and coaching and will soon release her first book, based on the Flow Method. For her, it was the natural next step, embodying her mission behind every venture: to help people heal, rise, and live healthier, happier lives.
"I'm so grateful, as my journey so far has been remarkable. But I know that I am meant to do more, to give more," she reflects. "After all, if I can reach five, 10, or 100 people instead of just one, then I can do more good in the world. My life's purpose is to live with peace and confidence while helping others do the same. It's time for me to give back, to honor those who have helped me along the way. In fact, we have a family motto: comfy/cozy/happy/free. I don't let fear stop me anymore. Because it's not about me. It's about you."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
The Head and the Heart: Managing a ‘Silent Epidemic'
Cardiovascular disease (CVD) is the leading cause for premature mortality in patients with mental illness, particularly those with severe psychiatric disorders. The numbers bear out the link: The life expectancy of a person with severe mental illness is 15-20 years shorter than that of unaffected individuals, largely thanks to the effects of cardiac conditions. Patients with depression have a two to fourfold increased risk for developing CVD and a two to fourfold higher risk for mortality after experiencing a cardiac event compared to individuals without depression. A panel discussion at the 2025 annual meeting of the European Society of Cardiology held in Madrid, Spain, in conjunction with the Inter-American Society of Cardiology explored the intersection of the heart and the mind. Panelist Donata Kurpas MD, PhD, of Wroclaw Medical University, in Wrocław, Poland, called the burden of CVD in people with mental illness a 'silent epidemic' and encouraged attendees to 'rethink cardiovascular prevention' in the psychiatric conditions of their patients. Historically, cardiologists 'haven't paid too much attention to psychiatric symptoms, such as anxiety or depressive mood, and psychiatrists haven't spent much time looking for cardiovascular risk factors in their patients,' Panelist Maria Manuela Neves Abreu, MD, of the University of Lisbon, in Lisbon, Portugal, told Medscape Medical News . But this fragmentation has done a disservice to patients who were psychiatrically ill with CVD. Abreu said she encourages 'collaborative approach, which should be a team effort between cardiologists and psychiatrists.' 'It's important for all of us, as cardiologists and as doctors, to remind ourselves to try not to treat only the disease but rather, as much as realistically possible, to treat the patient as a whole,' said Glenn Levine, a professor of medicine at the Baylor College of Medicine and chief of the Cardiology Section at the Michael E. DeBakey VA Medical Center, in Houston. Complex Biological Mechanisms Roger McIntyre, MD, professor of psychiatry and pharmacology at the University of Toronto, Toronto, Ontario, Canada, who was not a participant in the panel, said the intersection of CVD and psychiatric illness can be 'considered across different levels.' Biological and 'social and economic determinants that play a role' in both conditions, McIntyre, who was not a member of the panel, told Medscape Medical News . Both have biological, behavioral, psychological, and genetic etiologies. Abreu, a cardiologist and a psychiatrist, said the intersection of mental illness and CVD likely involves a 'complex biological mechanism that integrates the inflammatory and immune systems, and hypothalamic-pituitary-adrenal axis, the sympathetic nervous system, reduced heart rate variability, and platelet dysfunction' as well as 'several shared genetic features common to both.' Kurpas noted sleep disorders, stress, and autonomic dysfunction 'amplify cardiovascular risk.' Given the biological commonalities, it appears that addressing each condition can benefit the other and particularly improve cardiovascular health in people with psychiatric illness, McIntyre said. Cardiac Effects of Psychotropic Drugs, Psychiatric Effects of Cardiac Drugs Psychotropic drugs used to treat psychiatric conditions can have cardiovascular effects. These may induce arrhythmias and cardiometabolic disturbances such as weight gain, dyslipidemia, and hypertension. Abreu noted that selective serotonin reuptake inhibitors typically are used as first-line treatment for depression in patients with cardiac disorders 'because they're well-tolerated and safe, in terms of cardiac rhythm, blood pressure, and interaction with cardiologic medication.' On the other hand, she said, they can have disrupt platelet aggregation — an effect that is enhanced when they're taken with antiplatelet aggregation or anticoagulant drugs. And fluoxetine and fluvoxamine can interact with aspirin, nonsteroidal anti-inflammatory drugs, or anticoagulants. And escitalopram and citalopram 'require greater caution, when it comes to QT interval prolongation and bradyarrhythmias.' A review by Pina and colleagues summarized the cardiac effects of commonly-prescribed antidepressants. Certain second-generation antipsychotics can have adverse cardiac effects, — myocarditis, cardiomyopathy, tachycardia, and arrhythmias, notably, prolongation of the QT interval, which can increase mortality risk. Many of these drugs also have cardiometabolic effects. A 2020 review comparing 18 second-generation antipsychotics found olanzapine and clozapine to have the most metabolic side effects, while aripiprazole, brexpiprazole, cariprazine, lurasidone, and ziprasidone have the most benign metabolic profiles. Abreu recommended following the protocols outline in a consensus statement created jointly by four organizations, including the American Diabetes Association, which delineates a schedule of screening and monitoring for patients taking these agents. Second-generation antipsychotics are not the only psychotropic drugs with potential cardiometabolic effects, Abreu added. Some mood stabilizers also can affect heart health. In particular, valproic acid and lithium are associated with weight gain. 'When prescribing psychotropic medications, the approach is to 'start low and titrate slowly,' and to monitor patients for adverse side effects and interactions with cardiac medications,' Abreu advised. 'Choose medications with lower potential for adverse metabolic effects as initial therapy and make adjustments and dose reductions of medications to the lowest therapeutic doses when feasible.' She also recommended adjunctive strategies for patients taking second-generation antipsychotics, including starting metformin upon initiation of treatment initiation. Just as psychotropic drugs can affect the heart, cardiac drugs can have adverse psychiatric effects. For example, alpha- and beta-adrenergic blockers, angiotensin converting enzyme inhibitors, anti-arrhythmics, and statins can cause sedation, sleep disturbances, depression, and sometimes anxiety, and cardiovascular and psychotropic drugs can interact with one another. Far-Reaching Effects Psychosocial and lifestyle factors significantly affect cardiovascular risk in people with psychiatric illness. 'People with poor psychological health — be it depression, anxiety, or stress — are less likely to take their medications consistently and may be less likely and more averse to seeking evaluation of their symptoms,' Levine said. They 'may tend to exercise less, eat poorly, have less-controlled diabetes, and thus be more prone to developing metabolic syndrome.' McIntyre, board chair of the Depression and Bipolar Support Alliance, a US-based national organization focusing on mood disorders, including depression and bipolar disorder, highlighted poverty, inadequate access to care, malnutrition, the need for food stamps and childhood adversity, particularly, physical or sexual abuse, as risk factors associated with the combination of mental illness and CVD. The healthcare system, too, can aggravate the problem. 'This includes stigma, negative attitudes, discrimination toward patients [with mental illness] and disparities in cardiovascular care, often resulting in fewer diagnostic procedures and delayed treatment initiation,' Abreu said. Karl-Heinz Ladwig, PhD, MD, senior research professor at the Medical Faculty of the Technische Universität Muenchen, in Munich, Germany, and a member of the panel, elaborated on some of the lifestyle and behavioral patterns of patients with CVD and depressive comorbidity. These include tobacco use, greater likelihood of not returning to work following an myocardial infarction, and co-occurring sleep disturbances and insomnia. In addition, decreased ability to maintain intimate relationships may occur, with a 'mutually reinforcing triad of depressive symptoms, CVD, and erectile dysfunction.' Levine pointed to a 2021 scientific statement from the American Heart Association (AHA), which concluded that psychological health 'may be causally linked to biological processes and behaviors that contribute to and cause' CVD. Contributors to negative psychological health, include chronic stress and social stressors, such as social isolation and loneliness, work-related challenges, financial hardships, and discrimination; posttraumatic stress disorder; anger and hostility, anxiety, depression, and pessimism. The AHA statement, on which Levin was the first author, did not focus only on the deleterious impact of negative psychological states. It stressed that positive psychological health, including a sense of optimism and purpose, happiness and positive affect, mindfulness, and higher emotional vitality can improve psychological well-being and, in turn, cardiovascular health. Multidisciplinary Collaboration Multidisciplinary collaboration is a critical component of addressing cardiovascular health in people with mental illness. 'No single provider can address psychiatric, behavioral, and somatic needs alone,' Kurpas said. 'A collaborative model has been shown to improve detection, continuity, and accountability and significantly improve patient outcomes.' Cardiologists should keep mental health factors in mind, and psychiatrists should keep cardiac concerns on their radar. 'Collaborative care should be a team effort between cardiologists and psychiatrists,' Abreu said. McIntyre agreed. 'All persons with mental illness should be screened for cardiovascular disease and metabolic syndrome, and all persons with heart disease should be screened for depression, as depression is the most robust prognosticator of cardiovascular death in people' after a myocardial infarction. The AHA statement recommended the Patient Health Questionaire-2 depression screen tool as well as the Generalized Anxiety Disorder Questionnaire-2, which can be administered by staff such as nurses or medical assistants. Positive screens can open a discussion about additional symptoms and can be used for making appropriate referrals to mental health providers. The statement offers specific talking points that cardiologists can use when addressing these issues with their patients. Even in the absence of a formally filled-out measurement tool, it 'may become apparent during the patient interaction that the patient is depressed or unduly stressed,' Levine said. Many cardiologists 'don't feel comfortable formally diagnosing or treating patients for depression, but it's fair game and appropriate to gently mention to the patient that it seems like they may be depressed or stressed and gently inquire if they have interest in seeing a mental health professional, which we can help arrange a referral to,' he said. 'That's a time-efficient and nonthreatening way to talk to patients, acknowledge their symptoms, and offer a pathway forward if they're interested.' Patients might 'recoil' at the suggestion of a psychiatrist, due to cultural values or fear of stigma, Levine added. 'They're more likely to be amenable if you recommend a 'mental health professional.'' Specific approaches to behavioral counseling are laid out in the 2016 joint recommendations of the European Society of Cardiology, Ladwig said. They include cognitive-behavioral strategies to facilitate lifestyle changes; utilizing multimodal interventions integrating medical resources with education, enhancing physical activity, stress management, and counseling regarding psychosocial risk factors; and referral for psychotherapy, medication, or collaborative care. The AHA statement includes similar recommendation regarding interventions for psychiatric disorders or symptoms, including pharmacotherapy, psychotherapy —particularly cognitive-behavioral therapy — care management, stress management programs, meditation training, and mindfulness-based interventions. The bidirectional relationship between psychiatric disease and CVD, which can become a vicious cycle, each exacerbating the other. Cardiologists should be cognizant of the role that addressing psychiatric illness can have in improving cardiovascular outcomes. In the words of Ladwig, 'the brain heals the heart.' The opposite side of the coin is also true, according to McIntyre. Healing the heart can also benefit the brain. Addressing both together is optimal to improving both mental and cardiovascular health. Kurpas, Abreu, Ladwig, and Levine declared no relevant financial relationships. McIntyre had received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie and Atai Life Sciences.
Yahoo
an hour ago
- Yahoo
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025. 'We are delighted that the results of the Phase 2 program were accepted for presentation at the ERA 2025 congress. This allowed Vivoryon to share the outstanding improvements of varoglutamstat on kidney function (eGFR) with the scientific and medical expert community in the kidney space,' said Frank Weber, MD, CEO of Vivoryon. Presentation HighlightsVaroglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with potent anti-inflammatory and anti-fibrotic effects. VIVIAD and VIVA-MIND, two independent Phase 2 studies in the EU and U.S. showed a statistically significant and clinically meaningful improvement in a prospectively defined kidney function parameter, eGFR, in an elderly patient population. This improvement was consistent in both trials independently, replicated in the meta-analysis and pooled analysis, and provides converging evidence for this finding. Statistically significant differences between varoglutamstat and placebo were first observed at week 24 and were sustained until week 96. The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes compared to those without diabetes. The next step is planned to be a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). The main goal will be to investigate the efficacy on eGFR in this patient population and to obtain additional information on a potential effect on proteinuria and other kidney specific markers. Presentation Details Date: June 6, 2025Presentation time: 8:15 am CEST as part of the focused oral sessionTitle: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studiesVenue: Vienna, Austria Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics ### About Vivoryon Therapeutics is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the 'Company'), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'plan,' 'project,' 'predict,' 'should' and 'will' and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company's results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Investor ContactsVivoryon Therapeutics Manuela Bader, Director IR & CommunicationEmail: IR@ LifeSci AdvisorsSandya von der Weid Tel: +41 78 680 05 38Email: svonderweid@ Media ContactTrophic CommunicationsValeria Fisher or Verena SchossmannTel: +49 175 8041816 / +49 151 219 412 77Email: vivoryon@ Attachment 20250606_ERA_VVYSign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
A&E wait times reduced by 'Dragon's Den' idea
Waiting times in accident and emergency at Sutton-in-Ashfield's King's Mill Hospital have been reduced by moving some less seriously ill people to chairs instead of trolleys. Sherwood Forest Hospitals NHS Foundation Trust's executive board met on Thursday to discuss the effectiveness of a plan called Fit2Sit, which was introduced in January to tackle overcrowding and improve the flow of patients. It involves medics identifying which patients need assessment but do not need to be lying down on a trolley while they wait, with a separate room set aside to hold 19 patients. Julia Rose, lead nurse at King's Mill's A&E, said the staff-suggested idea had "dramatically reduced" overcrowding. The Local Democracy Reporting Service said the meeting was told the waiting time for non-admitted patients to be seen in A&E had dropped by about 40 minutes since the change – down from 196 minutes to 150 minutes. Meanwhile the average number of patients within the department's majors area, where patients need more intensive treatment, has dropped from 61 to 35. A total of 89% of patients are now offloaded by ambulance crews within 30 minutes of arrival, compared to 80% in December 2024. Richard Kemp, divisional director of nursing for urgent and emergency care at the trust, told the board: "We can keep our clinicians in consulting rooms [and] keep patients due an assessment in a private area. "If necessary with ongoing investigation, a patient can return to the waiting room while that happens, whereas all of those patients would have been in the majors space previously, contributing to the crowding in that area." About £12,600 was spent on Fit2Sit from money raised by the trust's Daffodil Volunteers fund, including £5,000 awarded from a "Dragon's Den" initiative, which involves hospital staff pitching their own ideas to managers about how to solve problems. Board chairman Graham Ward said: "The biggest positive is this came from our staff, their idea, their approach to how we can improve our patient experience." Follow BBC Nottingham on Facebook, on X, or on Instagram. Send your story ideas to eastmidsnews@ or via WhatsApp on 0808 100 2210. Local Democracy Reporting Service Sherwood Forest Hospitals NHS Foundation Trust
